Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|April 21, 2017

Comorbidity Conundrums and Other Brain Teasers

Author(s)Natalie Timoshin

An update on emerging trends in psychosomatic medicine to help clinicians address mental health stressors in psychiatric and medical settings.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

kratom

Kratom Component in Clinical Trial for Opioid Use Disorder

ByKenneth J. Bender, PharmD, MA

August 21st 2026

opioids

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

ByChristian Heidbreder, PhD

August 20th 2026

drug testing

Let’s Talk About Drug Testing

ByEvan S. Schwarz, MD, FACEP, FACMT, FASAM

August 19th 2026

2026 Conference Insights: ASCP

ByHeidi Anne Duerr, MPH,Leah Kuntz,Jessica Walters

July 23rd 2026

data

2026 Conference Insights: APA

ByJessica Walters,Leah Kuntz

July 23rd 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG